Wei L L, Katzenellenbogen B S, Robertson D W, Simpson D M, Katzenellenbogen J A
Breast Cancer Res Treat. 1986;7(2):77-90. doi: 10.1007/BF01806792.
We have prepared two analogs of the antiestrogen tamoxifen that incorporate known DNA-crosslinking functions, a chloroethyl nitrosourea and a nitrosocarbamate moiety, and we have tested their bioactivities in cultures of human breast cancer cells. Both compounds bind to the estrogen receptor from MCF-7 cells, with relative binding affinities of 0.18% for the nitrosocarbamate derivative and 0.35% for the nitrosourea derivative, while the affinity of tamoxifen is 1.8%, and that of estradiol is set at 100%. The tamoxifen-nitrosocarbamate compound demonstrated a dose-related cytotoxicity by the colony formation and cell proliferation assays that was not blocked by estradiol in either estrogen receptor-positive MCF-7 cells or estrogen receptor-negative MDA-MB-231 cells, and thus, was not studied further. Tamoxifen-nitrosourea (TAM-NU) showed dose-related cytotoxicity in MCF-7 cells that was blocked by estradiol, whereas its activity in MDA-MB-231 cells was unaffected by estradiol. N-2-(4-t-butylphenoxy)ethyl-N'-chloroethyl-N'-nitrosourea (BPE-NU), a control compound which contains the nitrosourea moiety but does not bind to the estrogen receptor, had no effect on cell proliferation or colony formation in MCF-7 cells, but was very inhibitory in the receptor-negative MDA-MB-231 cells. In contrast, TAM-NU was more active in the receptor-positive MCF-7 cells than in the MDA-MB-231 line. Thus, because TAM-NU appears to be active selectively against the receptor-positive cell line, and because this activity is suppressible by estradiol, its cytotoxic effect seems to be mediated via the estrogen receptor. However, since TAM-NU is active only in prolonged treatment protocols, it appears likely that its cytotoxic activity results from the hormone antagonistic effect of the hydrolysis product of TAM-NU (bis-desmethyltamoxifen), rather than from a direct receptor-mediated, DNA-directed cytotoxic action of TAM-NU itself. This study stresses the need for the use of appropriate control compounds and cell systems in order to assess whether the toxic activity displayed by hormone-cytotoxic conjugates is mediated by receptor interactions and whether it operates through the intended toxic mechanism.
我们制备了两种抗雌激素他莫昔芬的类似物,它们引入了已知的DNA交联功能基团,即氯乙基亚硝基脲和亚硝基氨基甲酸酯部分,并在人乳腺癌细胞培养物中测试了它们的生物活性。两种化合物都能与MCF-7细胞中的雌激素受体结合,亚硝基氨基甲酸酯衍生物的相对结合亲和力为0.18%,亚硝基脲衍生物为0.35%,而他莫昔芬的亲和力为1.8%,雌二醇的亲和力设定为100%。通过集落形成和细胞增殖试验,他莫昔芬-亚硝基氨基甲酸酯化合物表现出剂量相关的细胞毒性,在雌激素受体阳性的MCF-7细胞或雌激素受体阴性的MDA-MB-231细胞中,这种毒性均未被雌二醇阻断,因此未作进一步研究。他莫昔芬-亚硝基脲(TAM-NU)在MCF-7细胞中表现出剂量相关的细胞毒性,且可被雌二醇阻断,而其在MDA-MB-231细胞中的活性不受雌二醇影响。N-2-(4-叔丁基苯氧基)乙基-N'-氯乙基-N'-亚硝基脲(BPE-NU)是一种对照化合物,含有亚硝基脲部分但不与雌激素受体结合,对MCF-7细胞的增殖或集落形成没有影响,但对受体阴性的MDA-MB-231细胞有很强的抑制作用。相比之下,TAM-NU在受体阳性的MCF-7细胞中比在MDA-MB-231细胞系中更具活性。因此,由于TAM-NU似乎对受体阳性细胞系具有选择性活性,且这种活性可被雌二醇抑制,其细胞毒性作用似乎是通过雌激素受体介导的。然而,由于TAM-NU仅在延长的治疗方案中具有活性,其细胞毒性活性似乎是由TAM-NU的水解产物(双去甲基他莫昔芬)的激素拮抗作用引起的,而不是由TAM-NU本身直接的受体介导、DNA导向的细胞毒性作用引起的。这项研究强调了使用合适的对照化合物和细胞系统来评估激素-细胞毒性缀合物所显示的毒性活性是否由受体相互作用介导以及它是否通过预期的毒性机制起作用的必要性。